Oxxon Pharmaccines Inc.
This article was originally published in Start Up
Executive Summary
One of the challenges surrounding the development of new vaccines has been inducing a strong enough immune response to protect the recipient from future infections, or to eradicate existing infection. The founding scientists of Oxxon Pharmaccines found that a particular combination of immunizations, using different vectors to deliver the same antigen in a sequence dependent upon priming and timing, created a high T-cell response. The scientists filed a patent around their so-called {Prime-Boost} technology, which has potential in a whole range of diseases, including hepatitis B and melanoma.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?